Current Indications and Future Landscape of Bispecific Antibodies for the Treatment of Lung Cancer

被引：2

作者：

Arasanz, Hugo ^{[1
,2
]}

Chocarro, Luisa ^{[3
]}

Fernandez-Rubio, Leticia ^{[3
]}

Blanco, Ester ^{[3
,4
]}

Bocanegra, Ana ^{[3
]}

Echaide, Miriam ^{[3
]}

Labiano, Ibone ^{[2
]}

Huerta, Ana Elsa ^{[2
]}

Alsina, Maria ^{[1
,2
]}

Vera, Ruth ^{[1
,2
]}

Escors, David ^{[3
]}

Kochan, Grazyna ^{[3
]}

机构：

[1] Hosp Univ Navarra, Med Oncol Dept, Inst Invest Sanitaria Navarra IdiSNA, Pamplona 31008, Spain

[2] Inst Invest Sanitaria Navarra IdiSNA, Oncobiona Grp, Navarrabiomed, Pamplona 31008, Spain

[3] Inst Invest Sanitaria Navarra IdiSNA, Oncoimmunol Grp, Navarrabiomed, Pamplona 31008, Spain

[4] Inst Invest Sanitaria Navarra IdiSNA, Div Gene Therapy & Regulat Gene Express, Ctr Invest Med Aplicada CIMA, Pamplona 31008, Spain

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2023年 / 24卷 / 12期

关键词：

lung cancer; bispecific; nanobodies; NSCLC; SCLC; targeted therapies; TYROSINE KINASE INHIBITORS; ACQUIRED-RESISTANCE; OPEN-LABEL; CHEMOTHERAPY; VEMURAFENIB; COBIMETINIB; MECHANISMS; NANOBODIES; NIVOLUMAB;

D O I：

10.3390/ijms24129855

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Bispecific antibodies are a promising type of therapy for the treatment of cancer due to their ability to simultaneously inhibit different proteins playing a role in cancer progression. The development in lung cancer has been singularly intense because of the increasingly vast knowledge of the underlying molecular routes, in particular, in oncogene-driven tumors. In this review, we present the current landscape of bispecific antibodies for the treatment of lung cancer and discuss potential scenarios where the role of these therapeutics might expand in the near future.

引用

页数：12

共 50 条

[41] Changes in the treatment landscape for metastatic urothelial cancer: current therapy and future directions
Yeon, Sang Hoon
Lee, Hyo Jin
JOURNAL OF MENS HEALTH, 2022, 18 (05)
[42] Tumor-Antigen-Binding Bispecific Antibodies for Cancer Treatment
Weidle, Ulrich H.
Kontermann, Roland E.
Brinkmann, Ulrich
SEMINARS IN ONCOLOGY, 2014, 41 (05) : 653 - 660
[43] Development of claudin 6 bispecific antibodies for treatment of ovarian cancer
Rucker, Joseph
Doolan, Kyle
Tyrell, Breanna
Lobley, Anna
Molino, Nick
Shema, Kristen
Guldner, Kyle
Cunningham, Alyssa
Chambers, Ross
Payne, Riley
CANCER RESEARCH, 2022, 82 (12)
[44] Bispecific antibodies for treatment of cancer in experimental animal models and man
Kroesen, BJ
Helfrich, W
Molema, G
de Leij, L
ADVANCED DRUG DELIVERY REVIEWS, 1998, 31 (1-2) : 105 - 129
[45] Bispecific antibodies for the treatment of neuroblastoma
Espinosa-Cotton, Madelyn
Cheung, Nai-Kong, V
PHARMACOLOGY & THERAPEUTICS, 2022, 237
[46] Bispecific antibodies for the treatment of hemophilia A
Shima, Midori
EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (08) : 1029 - 1042
[47] Immunotherapy for Prostate Cancer: Current Indications and Future Prospects
Small, Eric J.
HUMAN GENE THERAPY, 2010, 21 (10) : 1379 - 1379
[48] Lapatinib and breast cancer: current indications and outlook for the future
Moreira, Cynthia
Kaklamani, Virginia
EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (08) : 1171 - 1182
[49] Fulvestrant in 2004: current and future indications for breast cancer
不详
EJC SUPPLEMENTS, 2004, 2 (09): : 65 - 66
[50] Bispecific antibodies for cancer therapy
Chames, Patrick
Baty, Daniel
CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2009, 12 (02) : 276 - 283

← 1 2 3 4 5 →